suPAR: An Inflammatory Mediator for Kidneys

suPAR: An Inflammatory Mediator for Kidneys

Background: Inflammation is a common feature of many kidney diseases. The implicated inflammatory mediators and their underlying molecular mechanisms however are often not clear. Summary: suPAR is the soluble form of urokinase-type plasminogen activator receptor (uPAR), associated with inflammation...

Full description

Bibliographic Details
Main Authors:	Yashwanth Reddy Sudhini, Changli Wei, Jochen Reiser
Format:	Article
Language:	English
Published:	Karger Publishers 2022-06-01
Series:	Kidney Diseases
Subjects:	soluble urokinase-type plasminogen activator receptor kidney integrin covid-19 biomarker therapeutics
Online Access:	https://www.karger.com/Article/FullText/524965

Similar Items

The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults
by: Niklas Fabio Wohlwend, et al.
Published: (2023-09-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
by: Burcin Özdirik, et al.
Published: (2020-05-01)

suPAR as a prognostic biomarker in sepsis
by: Donadello Katia, et al.
Published: (2012-01-01)

suPAR as a marker of infection in acute kidney injury – a prospective observational study
by: Anna Hall, et al.
Published: (2018-08-01)

Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients
by: Esben Iversen, et al.
Published: (2020-06-01)

suPAR to Risk-Stratify Patients With Malaria
by: Veselina Stefanova, et al.
Published: (2022-06-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients
by: Ria M. Holstein, et al.
Published: (2022-06-01)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
by: Salim S. Hayek, et al.
Published: (2018-05-01)

suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients
by: Jeppe Meyer, et al.
Published: (2018-02-01)

suPAR na avaliação do prognóstico após permanência na unidade de terapia intensiva: um estudo piloto
by: Joana Silvestre, et al.
Published: (2019-01-01)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
by: Ourania S. Kotsiou, et al.
Published: (2022-10-01)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
by: Jan Simon Scharrenberg, et al.
Published: (2019-11-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Koh, Angela S., et al.
Published: (2018)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin′s Lymphoma
by: Shirin Kouhpayeh, et al.
Published: (2017-01-01)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women
by: Rafał Nikodem Wlazeł, et al.
Published: (2023-05-01)

Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department
by: Anne Byriel Walls, et al.
Published: (2021-08-01)

suPAR remains uninfluenced by surgery in septic patients with bloodstream infection
by: Rabensteiner, Jasmin, et al.
Published: (2016-07-01)

SuPAR-based choice of the management strategy in kidney transplant recipients with infection
by: N. V. Rapetskaya, et al.
Published: (2020-10-01)

Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury
by: Wenwen Zhang, et al.
Published: (2024-12-01)

The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study
by: Ruizhao Li, et al.
Published: (2021-01-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
by: Shengyuan Luo, et al.
Published: (2022-09-01)

suPAR, a Circulating Kidney Disease Factor
by: Changli Wei, et al.
Published: (2021-10-01)

Values of serum PCT, suPAR combined with severity scores for evaluating prognosis of septic shock patients
by: Wang Wenxin, et al.
Published: (2021-10-01)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
by: Noboru Ichihara, et al.
Published: (2017-10-01)

Can serum soluble urokinase plasminogen activator receptor be an effective biomarker in comparing the inflammatory response between laparoscopic and open appendectomy?
by: Basak Erginel, et al.
Published: (2023-06-01)

Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
by: Ioannis Griveas, et al.
Published: (2021-07-01)

Soluble Urokinase‐Type Plasminogen Activator Receptor, Changes of 24‐Hour Blood Pressure, and Progression of Chronic Kidney Disease
by: Jong Hyun Jhee, et al.
Published: (2021-01-01)

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis
by: Burcin Özdirik, et al.
Published: (2022-04-01)

Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
by: Per Lewander, et al.
Published: (2023-05-01)

Cardio‐Renal Biomarker Soluble Urokinase‐Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C‐Reactive Protein, and Renal Function
by: Julius Nikorowitsch, et al.
Published: (2020-04-01)

Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab
by: Nada Alachkar, et al.
Published: (2018-12-01)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
by: Nergiz Erkut, et al.
Published: (2016-05-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Angela S. Koh, et al.
Published: (2017-11-01)

Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study
by: Salim S. Hayek, et al.
Published: (2017-05-01)

The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention
by: Qin Y, et al.
Published: (2021-10-01)

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients
by: Ahmad S. Manshad, et al.
Published: (2022-01-01)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
by: Evangelos Terpos, et al.
Published: (2020-10-01)

Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study
by: Jian Chu, et al.
Published: (2024-01-01)

Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion
by: Synnove Norvoll Magnussen, et al.
Published: (2017-05-01)